Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs Under Armour Inc Class A (UA) Price & Performance

10X Genomics IncTrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs Under Armour Inc Class A — how do they compare? 10X Genomics Inc trades at $67.8 (market cap $8.55B), while Under Armour Inc Class A trades at $4.79 (market cap $2.15B). The key difference: 10X Genomics Inc is far larger — about 4× Under Armour Inc Class A's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.

TXGUA
Market Cap
$8.55B$2.15B
Sector
HealthConsumer Cyclical
52-Week High
$67.29$7.88
52-Week Low
$11.34$3.96
Enterprise Value
$8.08B$3.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Under Armour Inc Class A

Under Armour (UA) trades at $4.95, down 3.32% amid bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -9.99% and declining revenue trends. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. Cash flow remains negative, and the company faces challenges from softer consumer demand in key markets.

The outlook is cautious due to persistent revenue declines and negative margins. While analyst consensus leans slightly bullish with 40.3% buy ratings, significant risks include execution challenges and competitive pressures. Investors should weigh the potential for a turnaround against ongoing operational headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA